Share on StockTwits
 

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Paul Gitman unloaded 10,000 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the director now directly owns 59,425 shares of the company’s stock, valued at approximately $1,485,625. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on BSTC shares. Analysts at MKM Partners raised their price target on shares of BioSpecifics Technologies Corp. from $24.50 to $28.00 in a research note to investors on Thursday, January 9th. They now have a “buy” rating on the stock.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded down 2.45% on Thursday, hitting $24.32. The stock had a trading volume of 52,767 shares. BioSpecifics Technologies Corp. has a 52-week low of $15.01 and a 52-week high of $25.00. The stock has a 50-day moving average of $22.23 and a 200-day moving average of $19.54. The company has a market cap of $154.1 million and a price-to-earnings ratio of 37.21.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.13. Analysts expect that BioSpecifics Technologies Corp. will post $0.69 EPS for the current fiscal year.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.